Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 25, 2019. The filing reports a material definitive agreement entered into on the same date to secure funding for the clinical development of Onvansertib, a Phase 1b/2 oral PLK1 inhibitor for metastatic colorectal cancer.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance metrics.
- Total Proceeds: $1,675,000 aggregate issue price.
- Securities Issued: 1,100,000 shares of Common Stock, 200,000 shares of Series C Preferred Stock, and a Warrant exercisable for 900,000 shares of Common Stock.
- Warrant Terms: Exercise price of $0.627 per share; exercisable until January 25, 2024.
- Preferred Stock Conversion: Each Series C share converts into 10 shares of Common Stock, subject to a 4.99% beneficial ownership limitation.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Stock and Warrant Subscription Agreement (SPA) with POC Capital, LLC. This transaction alters the company's capital structure through the issuance of unregistered equity securities and warrants. Additionally, the company filed a Certificate of Designations for the Series C Preferred Stock on January 28, 2019.
Outlook, Risks, and Management Commentary
Management announced the agreement to fund the Phase 1b/2 clinical trial of Onvansertib in patients with metastatic colorectal cancer. The funding is structured pursuant to a Master Services Agreement involving the Company, Integrium, LLC, and POC Capital, LLC. The securities were sold pursuant to Section 4(a)(2) of the Securities Act of 1933. No specific risks or contingencies beyond standard regulatory exemptions were detailed in the summary text.
Investor Verification Checklist
- Verify the full terms of the Stock and Warrant Subscription Agreement (Exhibit 10.1) and the Warrant (Exhibit 4.1).
- Review the Certificate of Designation for Series C Preferred Stock (Exhibit 3.1) to understand voting rights and liquidation preferences.
- Confirm the status of the Phase 1b/2 clinical trial for Onvansertib as described in the press release (Exhibit 99.1).
- Assess the dilution impact of the 1,100,000 common shares and 900,000 warrant shares on existing shareholders.